Most Popular
Newsletter
Breaking News
Cyagen and Lumiere Therapeutics Forge Strategic Partnership to Advance Commercialization of the enCas12Ultra Base Editing System
Nov 18, 2024
Recently, Cyagen (Suzhou) Biosciences Co., Ltd. ("Cyagen") signed a strategic cooperation agreement with Lumiere Therapeutics (Suzhou) Co., Ltd. ("Lumiere") to jointly advance the commercialization of Lumiere’s enCas12Ultra. Read More >
Newsletter
Breaking News
Cyagen's Partner InnoVec Receives US FDA Investigational New Drug Approval for IVB103 Clinical Trials
Aug 09, 2024
On July 26, 2024, InnoVec's IVB103 injection received early Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), which may now proceed to the clinical trial phase. Read More >
Breaking News
Newsletter
Cyagen and Biointron Announce Strategic Alliance to Advance Antibody Drug Discovery
Mar 28, 2024
Cyagen Biosciences (Suzhou) Inc. (“Cyagen Biosciences”) and Shanghai BaiYing Bio-Technology Co., Ltd. (“Biointron”) have signed a strategic cooperation agreement. Read More >
Newsletter
Breaking News
Cyagen Congratulates Our Partner INNOVEC on Receiving FDA Pediatric Rare Disease Designation (RPDD) for IVB102 Injection
Jan 23, 2024
The United States Food and Drug Administration (FDA) granted Beijing InnoVec Biotherapeutics’ InnoVex IVB102 injection the Rare Pediatric Disease Designation (RPDD) on January 10, 2024. Innovec is now one step closer to being eligible for the Rare Pediatric Disease Priority Review Voucher (PRV) for the treatment of rare pediatric diseases with the InnoVex IVB102 injection in the United States. Read More >
Breaking News
Newsletter
HistoWiz and Cyagen Collaborate to Streamline Histopathology for Academic and Preclinical Mouse and Rat Model Research
Oct 23, 2023
SALT LAKE CITY, Utah–AALAS 2023–Booth #2717– (October 23, 2023)--HistoWiz, a leading provider of histology and slide archiving services, and Cyagen Biosciences, an AI-enabled CRO company specializing in custom genetically engineered animal and cell models for research, announced today at the American Association for Laboratory Animal Science (AALAS) a strategic co-marketing partnership to streamline histopathology services. Read More >
Newsletter
Cyagen CEO Lance Han - Pushing Therapeutic Advances Through Modelling
Apr 24, 2023
Cyagen Biosciences CEO Lance Han was recently featured in an interview with CEO Insights Asia Magazine. In the interview, Han discussed his vision for the future of biotech and gene editing and shared insights on how Cyagen is pioneering innovation in cell and gene therapy research through data-driven solutions. Additionally, Han was recognized by the magazine as one of the TOP 10 TSINGHUA UNIVERSITY ALUMNI LEADERS - 2023, a prestigious accolade that showcases his exceptional leadership skills and contributions to the biotech industry. Read More >
Breaking News
Newsletter
Cyagen and Landau Strengthen Cooperation to Accelerate the Research and Development of AI-designed AAV Gene Therapy Vectors
Dec 12, 2022
Recently, Cyagen and Guangdong Landau Biotechnology Co., Ltd. (hereinafter referred to as "Landau Biotech") strengthened their strategic partnership on the basis of the original strategic cooperation. Read More >
Video
Newsletter
Breaking News
Q&A
The First Artificial Chief Scientific Officer: AI Marvin
Nov 21, 2022
Have you ever wondered what the future of science education looks like? Many envision a future of readily accessible science knowledge and facts presented by intelligent, interactive teachers. Read More >
Newsletter
3rd Annual Gene Therapy for Ophthalmic Disorders Meeting in Review
Oct 31, 2022
Cyagen representatives recently attended The 3rd Annual Gene Therapy for Ophthalmic Disorders meeting with 150+ stakeholders and industry leaders in ophthalmic gene therapy. The event brought together ophthalmology experts with world-class learning tracks to address the challenges faced in the preclinical stages and in clinical development, aiming to get these drugs to the ophthalmic gene therapy patients who need them as fast as possible. Read More >
Newsletter
Let's Meet at The 3rd Annual Gene Therapy for Ophthalmic Disorders in September!
Sep 05, 2022
The 3rd Annual Gene Therapy for Ophthalmic Disorders meeting is bringing you even more world class content, bringing you two tracks of learning to tackle the pressing challenges faced in the pre-clinical stages and in clinical development. This includes challenges faces with drug targets including wet AMD, dry AMD, DME, IRDs and more. Read More >